Jade Biosciences (JBIO) Accumulated Expenses (2020 - 2026)

Jade Biosciences (JBIO) has 7 years of Accumulated Expenses data on file, last reported at $14.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 824.21% year-over-year to $14.9 million; the trailing twelve-month figure through Mar 2026 stood at $14.9 million (up 824.21% YoY), and the FY2025 full-year result was $9.4 million, up 128.34% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $14.9 million, up from $9.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $14.9 million in Q1 2026 and bottomed at $1.3 million in Q2 2022.
• The 5-year median for Accumulated Expenses is $4.7 million (2024), against an average of $6.4 million.
• The widest annual swing landed in 2025, when Accumulated Expenses sank 83.52%; it then surged 824.21% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $2.8 million in 2022, then soared by 438.75% to $14.8 million in 2023, then plunged by 72.17% to $4.1 million in 2024, then surged by 128.34% to $9.4 million in 2025, then jumped by 57.68% to $14.9 million in 2026.
• The last three Accumulated Expenses figures came in at $14.9 million (Q1 2026), $9.4 million (Q4 2025), and $14.0 million (Q3 2025), per Business Quant data.

Peer Comparison